Myopic choroidal neovascularization (mCNV) is one of the most sight-threatening complications of pathological myopia. Currently, anti–vascular endothelial growth factor (VEGF) therapy is a standard treatment strategy for mCNV.1 Once the CNV activity was ceased after initiating the therapy, patients were followed up every month and were generally treated as soon as recurrence was observed (pro re nata; PRN protocol). The continuous visits for examination pose a burden for patients and health care providers.
